Shell Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Shell Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$47K	Sell	701 -939	-57%	-$69.6K	﹤0.01%	885
2025 Q2	$137K	Sell	1,640 -64	-4%	-$4.79K	﹤0.01%	900
2025 Q1	$122K	Sell	1,704 -74	-4%	-$3.6K	0.01%	965
2024 Q4	$80K	Hold	1,778	–	–	﹤0.01%	1090
2024 Q3	$90K	Buy	+1,778	New	+$85.1K	﹤0.01%	1069
2024 Q1	$77K	Sell	1,881 -215	-10%	-$9.72K	﹤0.01%	1084
2023 Q4	$84K	Buy	+2,096	New	+$59.6K	﹤0.01%	1104

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Shell Asset Management's SLNO Position: Q3 2025 in Review

Shell Asset Management reduced its Soleno Therapeutics (SLNO) stake by 57% in Q3 2025, selling an estimated $69.6K and leaving 701 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #885.

Shell Asset Management first reported a position in SLNO in Q4 2023 and has held it in 7 quarters since. The position peaked at $137K in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

Shell Asset Management held 701 shares of Soleno Therapeutics worth $47K as of Q3 2025.
Shell Asset Management sold 939 Soleno Therapeutics shares in Q3 2025, an estimated $69.6K.
Soleno Therapeutics made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #885 holding.
Shell Asset Management first reported a position in Soleno Therapeutics in Q4 2023 and has held it in 7 quarters since.
Shell Asset Management's Soleno Therapeutics position peaked at $137K in Q2 2025.
240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.